Advanced Solutions
for Advanced Pathology
CD138/syndecan-1 (B-A38)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45173 IMPATH CD138 RTU M (B-A38)
50 Tests
44220 CD138 RTU M (B-A38)
7 ml Ready To Use
44463 CD138 0,1 M (B-A38)
100 µl liquid Concentrated
44464 CD138 1 M (B-A38)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Membranous
Control
Tonsil
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CD138 is a protein encoded by a transmembrane (type I) heparan sulfate proteoglycan gene and is a member of the syndecan proteoglycan
family.
CD138, Syndecan 1, is expressed in the late stages of B-cell differentiation with progression towards plasma cells. Syndecan 1 is up-regulated
by WT-1 and in turn acts as a receptor for collagen, fibronectin and thrombospondin. It binds basic fibroblast growth factor, an angiogenic agent,
and thereby modulates neovascularisation. The free ectodomain of syndecan I suppresses proliferation of tumor cells.
Anti-CD138 is expressed in distinct stages of differentiation of normal lymphoid cells. It can be used to differentiate lymphoplasmacytic lymphoma
from marginal zone lymphoma. ALK+ large B-cell lyphoma (LBLC) usually strongly expresses CD138 whereas lineage-associated markers such
as anti-CD20 and anti-CD79a do not stain ALK+ LBLC. Anti-CD138 is immunoreactive with HHV8-associated primary effusion lymphoma even
though the lymphoma cells lack the expression of B-cell markers. Anti-CD138 is a good marker to identify and enumerate plasma cells, benign,
reactive, or malignant, in bone marrow biopsy specimens.
Plasma Cell Neoplasm and Lymphoproliferative Neoplasms
CD138
CD79a
EMA
MUM1
CD56 Cyclin D1 CD43
CD20
CD19
Plasma Cell Neoplasm
+
+
+
+
+
-/+
-
-/+
-
ALK + LBCL
+
-
+
+
-
-
-/+
-
-
Plasmablastic Lymphoma
+
+
+
+
-
-
-
-
-
HHV Associated LBCL
-
-
-
-
-
-
-
+/-
+/-
Primary Effusion
Lymphoma
+
-
+
+
-
-
-
-
-
Lymphoblastic Lymphoma
+
+
-
+/-
-
-
-
+
+
Splenic Marginal Zone
Lymphoma
-/+
+
-
+/-
-
-
-
+
+
Reference
1. Lampert IA, et al. Appl Immunohistochem Mol Morphol. 2005 Jun; 13(2):124-31.
2. Oksanen A, et al. J Clin Pathol. 2005 Apr; 58(4):376-81.
83
